M
3.33
-0.11 (-3.20%)
| Penutupan Terdahulu | 3.44 |
| Buka | 3.40 |
| Jumlah Dagangan | 73,274 |
| Purata Dagangan (3B) | 221,559 |
| Modal Pasaran | 7,397,928 |
| Harga / Jualan (P/S) | 1.75 |
| Harga / Buku (P/B) | 1.71 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 Apr 2025 |
| Margin Operasi (TTM) | -1,883.22% |
| EPS Cair (TTM) | -44.40 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 228.39% |
| Nisbah Semasa (MRQ) | 0.240 |
| Aliran Tunai Operasi (OCF TTM) | -19.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.58 M |
| Pulangan Atas Aset (ROA TTM) | -99.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,333.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Mainz Biomed N.V. | Menaik | Menaik |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.98% |
| % Dimiliki oleh Institusi | 11.06% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vontobel Holding Ltd. | 31 Dec 2024 | 0 |
| Julat 52 Minggu | ||
| Median | 14.00 (320.42%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Maxim Group | 14 Feb 2025 | 14.00 (320.42%) | Beli | 6.04 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Apr 2025 | Pengumuman | Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update |
| 27 Mar 2025 | Pengumuman | Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study |
| 03 Mar 2025 | Pengumuman | Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention |
| 20 Feb 2025 | Pengumuman | Mainz Biomed Expands into Switzerland with labor team w |
| 11 Feb 2025 | Pengumuman | Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month |
| 27 Jan 2025 | Pengumuman | Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements |
| 21 Jan 2025 | Pengumuman | Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |